Printer Friendly

Diagnostic HYBRIDS Announces Release of the New D3 IFA Enterovirus Identification Kit.

ATHENS, Ohio -- Diagnostic HYBRIDS announces the release of its D3 IFA Enterovirus Identification Kit for the qualitative identification of enteroviruses in cell culture by immunofluorescence. The kit, for in vitro diagnostic use, utilizes a blend of monoclonal antibodies developed in-house. These antibodies target enterovirus-specific antigens produced after a relatively short incubation period in the proprietary enterovirus cell system called Super E-Mix[TM], or conventional cells such as primary monkey kidney cells. The D3kit represents a product design improvement on current identification protocols that employ a non-specific, cellular induced protein that is not induced specifically by enteroviruses. When combined with the patented Diagnostic HYBRIDS Super E-Mix[TM] cell culture system, positive results can be obtained and confirmed in as little as 16 hours from all specimen types.

"The most recent Enterovirus Surveillance Report1 estimates approximately 11 to 15 million symptomatic enteroviral infections each year, "said Ronald Lollar, Senior Director of Product Management at Diagnostic HYBRIDS. "Over half of these infections are not identified in cerebral spinal fluid. Cell culture is the only FDA-cleared methodology for these types of specimens. The new D3 IFA Enterovirus Identification Kit was developed to meet the need for sensitive and specific identification of Enterovirus in these cell cultures."

The D3 IFA Enterovirus Identification Kit adds a key component to the Diagnostic HYBRIDS Rapid Enterovirus culture system. The complete system includes Flocked Swab/UTM for specimen collection and transport, Super E-Mix cells that promote the rapid isolation of the Enterovirus family of viruses in a single culture system, and the D3 IFA Enterovirus Identification Kit.

About Diagnostic HYBRIDS

Diagnostic HYBRIDS invents, develops, manufactures, and sells innovative diagnostic and analytical products for a wide range of viral respiratory diseases, herpes virus infections, and other specific viral and thyroid diseases. The company also develops and commercializes innovative and genetically engineered cell-based detection products for the pharmaceutical and biotechnology industry, with an initial focus on pharmacology assays and products that measure drug clearance and anti-viral interventions with drugs and vaccines. The company is certified to ISO 13485 standards and manufactures live continuous and primary cell cultures for clinical diagnostics and pharmacology assays from its headquarters in Athens, OH. Diagnostic HYBRIDS was named one of the 500 Fastest Growing Companies in America in 2004 and 2005 by Inc. Magazine. The company is a pillar member of BioOhio, a statewide organization of bioscience companies accelerating the bioscience and healthcare economy in Ohio. For more information, please visit www.dhiusa.com.

1 Enterovirus Surveillance - United States, 1970--2005, Nino Khetsuriani, MD, Ashley LaMonte-Fowlkes, MPH, M. Steven Oberste, PhD, Mark A. Pallansch, PhD Division of Viral Diseases, National Center for Immunization and Respiratory Diseases
COPYRIGHT 2007 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2007, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Date:Apr 26, 2007
Words:439
Previous Article:America First Tax Exempt Investors, L.P. Announces Exercise of Over-Allotment Option.
Next Article:Conexant Reports Financial Results for the Second Quarter of Fiscal 2007.


Related Articles
First epidemic of echovirus 16 meningitis in Cuba. (Dispatches).
Surveillance for unexplained deaths and critical illnesses due to possibly infectious causes, United States, 1995-1998. (Research).
Geographic association of Rickettsia felis-infected opossums with human murine typhus, Texas. (Research).
Disease surveillance and the academic, clinical, and public health communities. (Synopses).
Acute hemorrhagic conjunctivitis caused by coxsackievirus A24 variant, South Korea, 2002. (Dispatches).
Aseptic meningitis epidemic during a West Nile virus avian epizootic.
SARS exposure and emergency department workers.
Recombinant human enterovirus 71 in hand, foot and mouth disease patients.
Echovirus 30, Jiangsu Province, China.
Dengue type 3 virus, Saint Martin, 2003-2004.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters